Astria Therapeutics Announces Shareholder Approval of Merger with BioCryst

What Happened

• Astria Therapeutics, Inc. announced that its stockholders approved the Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc. at a special meeting on January 21, 2026. The merger agreement was originally entered on October 14, 2025. As of the record date (December 9, 2025) there were 57,084,838 shares outstanding; 35,757,073 shares (≈62.64% of outstanding) were represented at the meeting, establishing a quorum.

Key Details

• Merger vote result: 35,673,135 votes For, 12,977 Against, 70,961 Abstentions.
• Advisory compensation vote (non-binding): 33,236,762 For, 2,035,104 Against, 485,206 Abstentions.
• Record date for voting: December 9, 2025; Special Meeting held January 21, 2026 in Boston.
• The adjournment proposal was not voted on because the Merger Proposal was approved.

Why It Matters

• Shareholder approval cleared a required stockholder vote under the Merger Agreement, removing a key procedural barrier to completing the transaction with BioCryst.
• The advisory (non-binding) vote on merger-related executive compensation also passed, which indicates investor support for the disclosed executive arrangements tied to the transaction.
• Investors should watch for subsequent filings and announcements (including closing conditions, regulatory approvals, and any timing updates) for the next steps in completing the merger.